Ironwood Pharmaceuticals, Inc. reported $389M of revenue over the trailing twelve months, +26% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $389M (to Q2 2026). Net income: $130M, trailing twelve months to Q2 2026. Free cash flow: $127M, trailing twelve months to Q4 2025. Operating margin: 54%, trailing twelve months to Q2 2026.

IRWDIronwood Pharmaceuticals, Inc.

Healthcare

$3.86+154% 1Y

$3.86

$1.4352 weeks$5.39

IRWD as reported

Ironwood Pharmaceuticals, Inc. reported $389M of revenue over the trailing twelve months, +26% on the year before. 11 reported series are charted on this page, each one as filed.

$389M

Revenue, trailing twelve months · to Q2 2026 · +26% against the twelve months before

Net income: $130M
Net income · −1747% year on year · trailing twelve months to Q2 2026
Free cash flow: $127M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: 54%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IRWD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$389M	+26%	Q2 2026
Net income	$130M	−1747%	Q2 2026
EPS	$0.77	−1383%	Q2 2026
Gross margin	99%	n/a	Q4 2020 · 22 quarters behind
Operating margin	54%	n/a	Q2 2026
Net margin	28%	n/a	Q2 2026
ROE	−37%	n/a	Q2 2026
ROA	21%	n/a	Q2 2026
ROIC	−33%	n/a	Q3 2025
Free cash flow	$127M	n/a	Q4 2025
P/E	5.01	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.